Recordati SpA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Recordati SpA with three other
pharmaceutical manufacturers in Europe:
Hikma Pharmaceuticals PLC
of the United Kingdom
sales of £944.31 million [US$1.16 billion]
of which 49%
was Injectable Pharmaceuticals),
Krka DD Novo Mesto
(1.16 billion Euro [US$1.24 billion]
of which 64%
was European Union), and
based in Finland
(1.02 billion Euro [US$1.08 billion]
of which 94%
was Pharmaceuticals Business).
During the year ended December of 2015, sales at
Recordati SpA were 1.05 billion Euro (US$1.11 billion).
increase of 6.1%
versus 2014, when the company's sales were 987.36 million Euro.
This was the fifth consecutive year of sales increases at Recordati SpA
(and since 2010, sales have increased a total of 51%).
Sales of Orphan Drugs saw an increase
that was more than double the company's growth rate: sales were up
24.3% in 2015, from
123.18 million Euro to 153.13 million Euro.